<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39441497</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8253</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology and therapy</Title><ISOAbbreviation>Neurol Ther</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40120-024-00671-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Real-world data are required to provide a greater understanding of the impact of ofatumumab on the ability to mount an effective immune response following the receipt of approved COVID-19 vaccinations. This retrospective real-world analysis aimed to describe the humoral immune response to COVID-19 vaccination during ofatumumab treatment in patients with multiple sclerosis (MS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from patients with MS treated with ofatumumab who were fully vaccinated against COVID-19 infection were abstracted from medical charts at four clinical sites in the USA. Patient characteristics and humoral response were summarized descriptively. Differences in humoral response were documented on the basis of vaccination status during ofatumumab treatment (i.e., after full vaccination and after booster vaccination) and prior disease-modifying treatment (DMT) exposure (i.e., DMT naïve, prior anti-CD20/sphingosine 1-phosphate [S1P] therapy, prior non-anti-CD20/S1P therapy). The sample size precluded formal statistical analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-eight patients were included. The mean (standard deviation) duration of ofatumumab treatment upon data collection was 20.4 (4.6) months (treatment ongoing for 35 [92%] patients). Definitive humoral response after full vaccination was documented for 34 patients, of whom 20 (60%) were seropositive. Definitive humoral response after booster vaccination was documented among five patients, of whom three (60%) were seropositive. Among patients who were DMT naïve prior to ofatumumab (n = 15), 73% were seropositive; among patients exposed to prior anti-CD20/S1P therapy (n = 14), 33% were seropositive; and among patients exposed to prior non-anti-CD20/S1P therapy (n = 9), 56% were seropositive. Patients naïve to DMT had been living with an MS diagnosis for a shorter duration than those experienced with DMTs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with MS receiving ongoing treatment with ofatumumab can mount a positive humoral response to a COVID-19 vaccination. Prior treatment with anti-CD20 or S1P DMTs may be a risk factor for lower humoral response.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dave</LastName><ForeName>Rahul H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Inova Medical Group-Neurology II, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crayton</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Center of Greater Washington, Washington, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miravalle</LastName><ForeName>Augusto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Ming-Hui</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, One Health Plaza East, Hanover, NJ, 07936, USA. mindy.tai@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyse</LastName><ForeName>Kerri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, One Health Plaza East, Hanover, NJ, 07936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghton</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>RTI Health Solutions, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitchens</LastName><ForeName>Abby</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>RTI Health Solutions, Ann Arbor, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkovich</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Los Angeles County General Hospital and Clinic, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neurol Ther</MedlineTA><NlmUniqueID>101637818</NlmUniqueID><ISSNLinking>2193-6536</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus 2 (SARS-CoV-2)</Keyword><Keyword MajorTopicYN="N">Medical records</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Ofatumumab</Keyword><Keyword MajorTopicYN="N">Real-world evidence</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39441497</ArticleId><ArticleId IdType="doi">10.1007/s40120-024-00671-0</ArticleId><ArticleId IdType="pii">10.1007/s40120-024-00671-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cross AH, Delgado S, Habek M, et al. Characteristics and outcome of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab (4123). Neurology. 2021;96:4123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.96.15_supplement.4123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId><ArticleId IdType="pmc">7402624</ArticleId></ArticleIdList></Reference><Reference><Citation>König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. 2023;94(1):19–22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327612</ArticleId><ArticleId IdType="pubmed">34670844</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220461</ArticleId><ArticleId IdType="pubmed">33958324</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864211012835</ArticleId><ArticleId IdType="pubmed">34035836</ArticleId><ArticleId IdType="pmc">8072850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatino JJ Jr, Mittl K, Rowles W, et al. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. Mult Scler Relat Disord. 2023;70:104484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104484</ArticleId><ArticleId IdType="pubmed">36608538</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2022;19(1):325–33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01165-9</ArticleId><ArticleId IdType="pubmed">34859382</ArticleId></ArticleIdList></Reference><Reference><Citation>Januel E, Hajage D, Labauge P, et al. Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open. 2023;6(6):e2319766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.19766</ArticleId><ArticleId IdType="pubmed">37351881</ArticleId><ArticleId IdType="pmc">10290250</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870–85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012753</ArticleId><ArticleId IdType="pubmed">34610987</ArticleId><ArticleId IdType="pmc">8601210</ArticleId></ArticleIdList></Reference><Reference><Citation>Holroyd KB, Healy BC, Conway S, et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: immune profiles and clinical outcomes. Mult Scler Relat Disord. 2022;67:104079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104079</ArticleId><ArticleId IdType="pubmed">35952457</ArticleId><ArticleId IdType="pmc">9330583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Wang L, Shen L, Tang K. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022;81:104102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104102</ArticleId><ArticleId IdType="pubmed">35759920</ArticleId><ArticleId IdType="pmc">9230320</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103251</ArticleId><ArticleId IdType="pubmed">34571415</ArticleId><ArticleId IdType="pmc">8426319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89–100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26251</ArticleId><ArticleId IdType="pubmed">34687063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, Aburashed R, Chinea AR, et al. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab. Mult Scler Relat Disord. 2023;79:104967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2023.104967</ArticleId><ArticleId IdType="pubmed">37769429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, De Seze J, Correale J, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis (RMS) patients from the phase 3 ASCLEPIOS I and II trials (1300). Neurology. 2021;96:1300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.96.15_supplement.1300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8812-0</ArticleId><ArticleId IdType="pubmed">29511864</ArticleId><ArticleId IdType="pmc">5937879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, Hauser S, Cross A, et al. Five-year safety of ofatumumab in people living with relapsing multiple sclerosis. Neurology. 2023;100:2942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000202906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>